Saudi Arabia's Biotech Strategy, H.E. Dr. Bandar Al-Knawy Explains

Saudi Arabia is positioning itself to become a global biotechnology hub with a National Biotechnology Strategy that targets adding $34.6 billion to non-oil GDP by 2040 and creating 11,000 new jobs by 2030. The strategy centers on vaccines, biomanufacturing, localization and genomics, and is being operationalized through institutional partnerships led by His Excellency Dr. Bandar bin Abdulmohsen Al‑Knawy, MD, CEO of the Ministry of National Guard Health Affairs (MNGHA) and president of King Saud bin Abdulaziz University for Health Sciences (KSAU‑HS). A high-profile partnership signed in November 2025 between the King Abdullah International Medical Research Center (KAIMRC) and the U.S. venture firm Flagship Pioneering includes an initial $70 million of Saudi-backed capital to enable early‑phase clinical trials inside the Kingdom.

“The objective is not simply to bring technologies into the Kingdom,” Al‑Knawy said. “We want partnerships that build capabilities, develop Saudi talent, advance joint research, support technology transfer and create innovations that can benefit patients in Saudi Arabia and internationally.”

Al‑Knawy made the remarks while outlining how a linked ecosystem — combining patient care, a medical university and a research institute — is intended to accelerate the path from laboratory discovery to clinical application. KAIMRC’s pact with Flagship Pioneering establishes a framework to run three Phase 1 trials and one Phase 2 trial of medicines from Flagship‑founded companies, using clinical facilities at KAIMRC, MNGHA and KSAU‑HS. The deal is backed by the initial $70 million and is explicitly framed as a capability‑building effort rather than a simple import of technology.

Despite the strategic ambitions, the sector faces material supply and capacity gaps. A 2025 survey of Saudi biotechnology professionals cited estimates that the sector imports up to 94% of its lab equipment and 89% of its reagents, and reported frequent delays obtaining materials for genetic testing. Organizers of the Riyadh Global Medical Biotechnology Summit (RGMBS), scheduled for September 14–16, 2026, expect more than 15,000 visitors from over 70 countries and are targeting more than 65 agreements and memoranda of understanding during the three‑day event — a visible test of the Kingdom’s ability to attract foreign partners and mobilize investment at scale.

Context and strategic priorities

• National targets: $34.6 billion added to non‑oil GDP by 2040; 11,000 new biotech jobs by 2030.
• Priority areas: vaccines, biomanufacturing and localization, and genomics.
• Key institutions: Ministry of National Guard Health Affairs (MNGHA), King Saud bin Abdulaziz University for Health Sciences (KSAU‑HS), King Abdullah International Medical Research Center (KAIMRC).
• Anchor partnership: KAIMRC–Flagship Pioneering collaboration with an initial $70 million commitment to enable early‑phase clinical trials in Saudi Arabia.

Looking ahead, Al‑Knawy emphasized durability: “The real test is not the September summit itself, but whether the partnerships it produces still exist a year later.” If partnerships deliver on capability building, technology transfer and talent development as envisioned, the Kingdom’s investment capacity and integrated health‑research infrastructure could narrow current supply dependencies and expand domestic R&D and manufacturing. The coming months — and the outcomes of planned agreements at the RGMBS — will indicate how rapidly the strategy moves from national aspiration to operational biotech ecosystem.